Heart Conditions clinical trials at UCSD
7 in progress, 4 open to eligible people
Amplatzer Amulet LAAO vs. NOAC
open to eligible people ages 18 years and up
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.
San Diego, California and other locations
iCLAS™ for Persistent Atrial Fibrillation
open to eligible people ages 18-80
Clinical study to evaluate the safety and efficacy of the Adagio AF Cryoablation System (iCLAS™) in the ablation treatment of symptomatic, persistent atrial fibrillation (PsAF). Data will be used to support a pre-market application (PMA)
San Diego, California and other locations
Substrate Versus Trigger Ablation for Paroxysmal Atrial Fibrillation
open to eligible people ages 21 years and up
This is a prospective randomized study to assess the safety and efficacy of FIRM (Focal Impulse and Rotor Modulation)-guided ablation for the treatment of symptomatic atrial fibrillation (AF). The study hypothesis is that the efficacy of AF elimination at 1 year will be higher by ablating patient-specific AF-sustaining rotors and focal sources by Focal Impulse and Rotor Modulation (FIRM) compared to conventional ablation alone (wide-area PV isolation).
San Diego, California and other locations
Comprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery
open to eligible people ages 40 years and up
Apply CT angiography, CT perfusion imaging and advanced image processing techniques to improve revascularization decision-making and surgical strategies in patients undergoing coronary artery bypass graft surgery.
San Diego, California and other locations
aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation
Sorry, in progress, not accepting new patients
This study is a prospective, multicenter, randomized (2:1) controlled study to evaluate the safety and effectiveness of the LARIAT System to percutaneously isolate and ligate the Left Atrial Appendage from the left atrium as an adjunct to planned pulmonary vein isolation (PVI) catheter ablation in the treatment of subjects with symptomatic persistent or longstanding persistent atrial fibrillation. This study will be conducted in two stages: - Limited Early Stage (Stage 1): up to 250 subjects at up to 65 sites. (COMPLETED, transitioned to Stage 2) - Pivotal Stage/ Phase III (Stage 2): up to 600 subjects at up to 65 sites. (COMPLETED) All subjects from both stages will be included in the primary analysis.
La Jolla, California and other locations
Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF
Sorry, not currently recruiting here
This prospective randomized study will assess the safety and efficacy of FIRM-guided ablation (FIRM+PVI) compared to pulmonary vein isolation (PVI) without FIRM, for the treatment of symptomatic atrial fibrillation.
San Diego, California and other locations
TactiFlex AF IDE Trial
Sorry, in progress, not accepting new patients
Prospective non-randomized parallel-assignment multi-center clinical investigation. The study design includes two subject cohorts: 1) PAF Main Study, and 2) PAF High Standard Power (HSP) Substudy. Subjects in the main study cohorts are to be treated using the full range of ablation power settings in the IFU. Subjects in the HSP Substudy are to be treated in the upper end of the recommended ablation power settings (40-50 Watts).
San Diego, California and other locations
Our lead scientists for Heart Conditions research studies include Ryan Reeves, MD Frederick Han, MD Andrew Kahn, MD.
Last updated: